• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Diamedica Therapeutics Inc (NQ: DMAC )

    4.370 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Diamedica Therapeutics Inc

    < Previous 1 2 3 4 5 Next >
    Three (3) Stocks Under $10 That Insiders Are Buying
    These small-cap names provide an opportunity that insiders are buying including deep value, growth, new technology, and AI. 
    Via MarketBeat
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    DiaMedica Therapeutics Announces Closing of $37.5 Million Private Placement
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2023
    Via Benzinga
    Earnings Preview: DiaMedica Therapeutics
    Via Benzinga
    DiaMedica Therapeutics's Earnings Outlook
    Via Benzinga
    DiaMedica Raises $37.5M Via Equity Offering, Aiding Development Activities For DM199
    DiaMedica Therapeutics Inc. (NASDAQ: DMAC) has entered into an agreement with accredited investors that have agreed to provide up to $37.5 million in gross proceeds through a  
    Via Benzinga
    DiaMedica Therapeutics Announces $37.5 Million Private Placement
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2023 Financial Results
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    DiaMedica Therapeutics Appoints David Wambeke as Chief Business Officer
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2022 Financial Results
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    DiaMedica Therapeutics Announces the Appointment of Biopharma Veteran Tanya Lewis to Its Board of Directors
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    $1 Million Bet On OmniAb? Check Out These 3 Penny Stocks Insiders Are Buying
    The Dow Jones closed lower by around 200 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or... 
    Via Benzinga
    DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2022 Financial Results
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    DiaMedica Therapeutics to Attend the 13th Annual Craig-Hallum Alpha Select Conference November 17, 2022
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    DiaMedica Therapeutics to Present at Credit Suisse 31st Annual Healthcare Conference
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    Why Meta Platforms Shares Dipped Around 25%; Here Are 77 Biggest Movers From Yesterday
    Gainers UserTesting, Inc. (NYSE: USER) shares jumped 91.7% to close at $7.40 after the company announced it will be acquired by Thoma Bravo and Sunstone Partners for $1.3 billion. The company also... 
    Via Benzinga
    DiaMedica Therapeutics Provides Update on ReMEDy2 Trial
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    Why Cyclerion Therapeutics Shares Traded Lower By Around 38%; Here Are 70 Biggest Movers From Yesterday
    Gainers Green Giant Inc. (NASDAQ: GGE) jumped 161.1% to close at $1.88 after dipping 29% on Wednesday. 
    Via Benzinga
    Why Revelation Biosciences Shares Are Trading Higher By 29%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
    Gainers Statera Biopharma, Inc. (NASDAQ: STAB) rose 98% to $0.2777. Statera Biopharma was recently granted European patent number EP3206708 titled "Methods And Compositions For The Treatment Of... 
    Via Benzinga
    DiaMedica Therapeutics Appoints Julie Daves as SVP, Clinical Development Operations
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    DiaMedica Therapeutics to Present at Lake Street’s 6th Annual Best Ideas Growth Conference
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    DiaMedica Therapeutics: Q2 Earnings Insights
      DiaMedica Therapeutics (NASDAQ:DMAC) reported its Q2 earnings results on Wednesday, August 10, 2022 at 04:30 PM. Here's what investors need to know about the announcement. 
    Via Benzinga
    DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2022 Financial Results
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    DiaMedica Therapeutics Earnings Preview
      DiaMedica Therapeutics (NASDAQ:DMAC) is set to give its latest quarterly earnings report on Wednesday, 2022-08-10. Here's what investors need to know before the announcement. 
    Via Benzinga
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.